Examples of the polyoxyl castor oil include polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, polyoxyl 40 castor oil, and others.

Examples of the polyoxyethylene polyoxypropylene glycol include polyoxyethylene (3) polyoxypropylene (17) glycol, polyoxyethylene (20) polyoxypropylene (20) glycol, polyoxyethylene (42) polyoxypropylene (67) glycol, polyoxyethylene (54) polyoxypropylene (39) glycol, polyoxyethylene (105) polyoxypropylene (5) glycol, polyoxyethylene (120) polyoxypropylene (40) glycol, polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene (196) polyoxypropylene (67) glycol, and others.

Examples of the polyoxyethylene polyoxypropylene cetyl ether include polyoxyethylene (20) polyoxypropylene (4) cetyl ether, polyoxyethylene (20) polyoxypropylene (8) cetyl ether, and others.

Examples of the polyoxyethylene alkyl ether include polyoxyethylene cetyl ether, polyoxyethylene lauryl ether, polyoxyethylene behenyl ether, polyoxyethylene arachyl ether, and others.

Examples of the glycerin fatty acid ester include glyceryl monocaprylate, glyceryl dicaprylate, glyceryl tricaprylate, polyglyceryl monocaprylate, polyglyceryl dicaprylate, polyglyceryl tricaprylate, glyceryl

CLAIMS

1. A pharmaceutical composition for application to the skin for treating allergic conjunctivitis, comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient, wherein the pharmaceutical composition is to be used in the administration to eyelid skin.

~~2. The pharmaceutical composition according to claim 1 for use in the administration to eyelid skin.~~

~~3~~2. The pharmaceutical composition according to claim 1 ~~or 2~~ for use in the administration to a patient once daily.

~~4. The pharmaceutical composition according to any one of claims 1 to 3 for treating allergic conjunctivitis.~~

~~5~~3. The pharmaceutical composition according to ~~any one of~~ claim~~s~~ 1 ~~to 4~~ or 2 with a viscosity of 150 Pa·s or less at 20 degrees Celsius.

~~6~~4. The pharmaceutical composition according to any one of claims 1 to ~~5~~3, wherein the pharmaceutical composition is ointment formulation, cream formulation or gel formulation.

~~7~~5. The pharmaceutical composition according to any one of claims 1 to ~~5~~3, wherein the pharmaceutical composition is cream formulation.

~~8~~6. The pharmaceutical composition according to any one of claims 1 to ~~7~~5, wherein the pharmaceutical composition is

water-in-oil emulsion.

~~9~~7. The pharmaceutical composition according to any one of claims 1 to ~~8~~6, wherein the concentration of the epinastine or a salt thereof is 0.05% (w/w).

~~10~~8. The pharmaceutical composition according to any one of claims 1 to ~~8~~6, wherein the concentration of the epinastine or a salt thereof is 0.5% (w/w).

~~11~~9. The pharmaceutical composition according to any one of claims 1 to ~~10~~8, wherein the epinastine or a salt thereof is epinastine hydrochloride.

~~12~~10. The pharmaceutical composition according to any one of claims 1 to ~~10~~8, wherein the epinastine or a salt thereof is epinastine.

~~13~~11. The pharmaceutical composition according to any one of claims 1 to ~~12~~10 which comprises one or more oil ingredients selected from the group consisting of a hydrocarbon, a wax, an oil and fat, an aliphatic carboxylic acid or a salt thereof, a fatty acid ester and a higher alcohol.

~~14~~12. The pharmaceutical composition according to any one of claims 1 to ~~12~~10 which comprises a surfactant.

~~15~~13. The pharmaceutical composition according to claim ~~14~~12, wherein the surfactant is glycerin fatty acid ester.

~~16~~14. The pharmaceutical composition according to claim ~~14~~12 or ~~15~~13, wherein the surfactant has a HLB of 3.0 to 6.0.

~~17~~15. The pharmaceutical composition according to any one of claims 1 to ~~16~~14, wherein the pharmaceutical composition is free of a paraben.

~~18~~16. A pharmaceutical composition for application to the skin comprising epinastine or a salt thereof in a concentration of 0.05 to 0.5% (w/w) as an active ingredient wherein the pharmaceutical composition is cream formulation in the form of water-in-oil emulsion for use in the administration to the eyelid skin once daily.

~~19~~17. A pharmaceutical composition for application to the skin comprising epinastine or a salt thereof in a concentration of 0.5% (w/w) as an active ingredient, wherein the pharmaceutical composition is cream formulation in the form of water-in-oil emulsion for use in the administration to the eyelid skin once daily.

~~20. A method of transferring a therapeutically effective amount of epinastine to an ocular tissue, by administering a pharmaceutical composition comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient to the eyelid skin.~~

~~21. A method of producing the sustained release of a therapeutically effective amount of epinastine from the eyelid skin to an ocular tissue, by administering a pharmaceutical composition comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active~~

~~ingredient to the eyelid skin.~~

~~22. The method according to claim 20 or 21, wherein the pharmaceutical composition is administered to a patient once daily.~~

~~23. The method according to any one of claims 20 to 22, wherein the ocular tissue is conjunctiva.~~

18. A pharmaceutical composition comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient, for use as a medicament to be administrated to eyelid skin.

19. Use of a pharmaceutical composition comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient, in the manufacture of a medicament for treating allergic conjunctivitis, wherein the medicament is to be used in the administration to eyelid skin.